{"filing":{"accession_number":"0001827635-26-000036","cik":"0001827635","ticker":"MANE","company_name":"Veradermics, Inc","form":"8-K","filing_date":"2026-10-19","report_date":"2026-10-19","primary_document":"mane-20261019.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1827635/000182763526000036/mane-20261019.htm"},"events":[{"id":35996,"run_id":33185,"accession_number":"0001827635-26-000036","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints with high statistical significance. This represents a material operational and clinical milestone for the late-stage biopharmaceutical company, demonstrating efficacy and safety data that support potential FDA approval and commercialization of its lead product candidate.","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-10-19","form":"8-K","submitted_at":null,"items":[{"id":40261,"accession_number":"0001827635-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints. This is a material operational/clinical milestone for a late-stage biopharmaceutical company, representing significant progress toward potential FDA approval and commercialization of its lead program. While not a traditional earnings release or M\u0026A event, the positive Phase 3 data is a transformative clinical development milestone that would materially affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:07:40.429433+00:00","company_name":"","ticker":null,"filing_date":""},{"id":40262,"accession_number":"0001827635-26-000036","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints with high statistical significance. This represents a material operational and clinical milestone for a late-stage biopharmaceutical company, demonstrating efficacy and safety data that support potential FDA approval and commercialization of its lead product candidate. While not a traditional earnings release or M\u0026A event, the successful Phase 3 data is a transformative operational achievement that would materially affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:07:40.429433+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40261,"accession_number":"0001827635-26-000036","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints. This is a material operational/clinical milestone for a late-stage biopharmaceutical company, representing significant progress toward potential FDA approval and commercialization of its lead program. While not a traditional earnings release or M\u0026A event, the positive Phase 3 data is a transformative clinical development milestone that would materially affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:07:40.429433+00:00","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-10-19"},{"id":40262,"accession_number":"0001827635-26-000036","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Veradermics announced positive Phase 3 clinical trial results for VDPHL01 in male pattern hair loss, with the drug meeting all primary and secondary endpoints with high statistical significance. This represents a material operational and clinical milestone for a late-stage biopharmaceutical company, demonstrating efficacy and safety data that support potential FDA approval and commercialization of its lead product candidate. While not a traditional earnings release or M\u0026A event, the successful Phase 3 data is a transformative operational achievement that would materially affect investor assessment of the company's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-19T13:07:40.429433+00:00","company_name":"Veradermics, Inc","ticker":"MANE","filing_date":"2026-10-19"}]}